Year Established :
2019
Total Number of Staff :
100-500
Main Competitive Advantages :
International Approvals/Standards,Experienced R&D Staff,Large Product Line,Contract Manufacturing (CRO,CMO),Quality Service
Business Type :
Service Provider,Manufacturer
R&D Capacity :
Own Brand
Main Sales Markets :
North America,Central/South America,Western Europe,Eastern Europe,Asia,Middle East,Africa
Product Range :
Adalimumab
Sotatercept
Evolocumab
Burosumab
Hyaluronidase
Lanadelumab
Romiplostim (CHO)
Emicizumab
Mepolizumab
Secukinumab
Dupilumab
Ustekinumab
Sarilumab
Tezepelumab
Guselkumab
Benralizumab
Casirivimab
Imdevimab
Palivizumab
Lecanemab
Denosumab
Pertuzumab
Daratumumab
Pembrolizumab
Atezolizumab
Durvalumab
Cetuximab
Panitumumab
Nivolumab
Rituximab
Trastuzumab
Faricimab
Ranibizumab
Bedinvetmab
Lokivetmab
Frunevetmab
Galcanezumab
Recombinant Zoster Vaccine
.............